Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Phase 3 Trial of Botulinum Neurotoxin Type A in Salivary Glands for Chronic Drooling in Cerebral Palsy
2010-021691-28Phase 3Active
- Sponsor
- Vall d'Hebron University Hospital
- Start
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A in hypersalivation, sponsored by Vall d'Hebron University Hospital. Primary endpoints: Efficacy in reducing drooling and Safety. Started Jan 2011; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
hypersalivation
Beyond the preview
Go deeper on 2010-021691-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021691-28.